According to B. Braun, this is the first FDA-approved prefilled syringe for Heparin Sodium Injection with an integrated needle protection device on the U.S. market. “Our products are designed to increase patient and clinician safety, while reducing medication errors and improving dosage accuracy and workflows. Obviously, efficient and economical manufacturing are equally important. Collaborating with Schreiner MediPharm allowed us to meet those needs,” says Leigh Nickens, Director of Marketing, Fluid Therapy and Injectable Drugs at B. Braun.
Needle-Trap complies with the U.S. NIOSH requirements for safe instruments and has been awarded 510(k) Pre-Market Notification by the FDA for marketing in the United States. Clinical staff benefit from reliable protection against needlestrick injuries because Needle-Trap’s activation is easy and irreversible. It is intuitive to use and requires no change in injection technique.
Due to its special construction, Needle-Trap can easily and cost-efficiently be integrated into existing pharmaceutical production processes. It requires only minor modifications of the application systems, no changes to secondary packaging, and minimal space during shipping, storage and disposal.
Needle-Trap is the only label-based needle protection system on the market. The needle protection label with an integrated trap marks the syringe and at the same time provides protection against needlestick injuries. Its construction
is unique: The plastic needle trap is an integral component of the marking label and serves to secure the needle after the injection has been performed.
